DaVita delivered solid financial performance in Q2 2024, with consolidated revenues reaching $3.19 billion and operating income of $506 million, representing a 15.9% operating margin. Diluted earnings per share was $2.50, while adjusted diluted EPS reached $2.59. The company generated robust operating cash flow of $799 million and free cash flow of $654 million.U.S. dialysis operations showed positive momentum with total treatments of 7.27 million, up 1.1% QoQ. Average patient service revenue per treatment increased to $390.22 from $384.54 in Q1 2024, driven by seasonal improvements in patient insurance deductibles and normal annual rate increases, partially offset by unfavorable payor mix changes.The company continued its capital return program, repurchasing 2.7 million shares at an average price of $140.14 per share. Additionally, DaVita extended the maturity date for $1.64 billion of Term Loan B-1 and maintained strong integrated kidney care growth with 71,300 risk-based patients representing approximately $5.4 billion in annualized medical spend.

DaVita delivered solid financial performance in Q2 2024, with consolidated revenues reaching $3.19 billion and operating income of $506 million, representing a 15.9% operating margin. Diluted earnings per share was $2.50, while adjusted diluted EPS reached $2.59. The company generated robust operating cash flow of $799 million and free cash flow of $654 million.U.S. dialysis operations showed positive momentum with total treatments of 7.27 million, up 1.1% QoQ. Average patient service revenue per treatment increased to $390.22 from $384.54 in Q1 2024, driven by seasonal improvements in patient insurance deductibles and normal annual rate increases, partially offset by unfavorable payor mix changes.The company continued its capital return program, repurchasing 2.7 million shares at an average price of $140.14 per share. Additionally, DaVita extended the maturity date for $1.64 billion of Term Loan B-1 and maintained strong integrated kidney care growth with 71,300 risk-based patients representing approximately $5.4 billion in annualized medical spend.